161 related articles for article (PubMed ID: 27586230)
1. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.
Whittle SB; Patel K; Zhang L; Woodfield SE; Du M; Smith V; Zage PE
Invest New Drugs; 2016 Dec; 34(6):685-692. PubMed ID: 27586230
[TBL] [Abstract][Full Text] [Related]
2. Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.
Li H; Wang Y; Chen Z; Lu J; Pan J; Yu Y; Zhao Y; Zhang H; Hu T; Liu Q; Yang J
Oncotarget; 2017 Jan; 8(4):5874-5884. PubMed ID: 27564113
[TBL] [Abstract][Full Text] [Related]
3. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
Sidarovich V; De Mariano M; Aveic S; Pancher M; Adami V; Gatto P; Pizzini S; Pasini L; Croce M; Parodi F; Cimmino F; Avitabile M; Emionite L; Cilli M; Ferrini S; Pagano A; Capasso M; Quattrone A; Tonini GP; Longo L
Mol Cancer Ther; 2018 Jul; 17(7):1405-1415. PubMed ID: 29695637
[TBL] [Abstract][Full Text] [Related]
4. Autophagic flux inhibition enhances cytotoxicity of the receptor tyrosine kinase inhibitor ponatinib.
Corallo D; Pastorino F; Pantile M; Mariotto E; Caicci F; Viola G; Ponzoni M; Tonini GP; Aveic S
J Exp Clin Cancer Res; 2020 Sep; 39(1):195. PubMed ID: 32962733
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies.
Singh A; Meier-Stephenson V; Jayanthan A; Narendran A
Curr Cancer Drug Targets; 2017; 17(6):569-584. PubMed ID: 27875952
[TBL] [Abstract][Full Text] [Related]
6. The ponatinib/gossypol novel combination provides enhanced anticancer activity against murine solid Ehrlich carcinoma via triggering apoptosis and inhibiting proliferation/angiogenesis.
El-Lakkany NM; Elkattan HH; Elsisi AE
Toxicol Appl Pharmacol; 2021 Dec; 432():115767. PubMed ID: 34699866
[TBL] [Abstract][Full Text] [Related]
7. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
Zage PE; Zeng L; Palla S; Fang W; Nilsson MB; Heymach JV; Zweidler-McKay PA
Cancer; 2010 May; 116(10):2465-75. PubMed ID: 20225331
[TBL] [Abstract][Full Text] [Related]
8. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
Jin B; Ding K; Pan J
Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
Kakodkar NC; Peddinti RR; Tian Y; Guerrero LJ; Chlenski A; Yang Q; Salwen HR; Maitland ML; Cohn SL
Pediatr Blood Cancer; 2012 Oct; 59(4):642-7. PubMed ID: 22147414
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
[TBL] [Abstract][Full Text] [Related]
13. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.
Lang JD; Hendricks WPD; Orlando KA; Yin H; Kiefer J; Ramos P; Sharma R; Pirrotte P; Raupach EA; Sereduk C; Tang N; Liang WS; Washington M; Facista SJ; Zismann VL; Cousins EM; Major MB; Wang Y; Karnezis AN; Sekulic A; Hass R; Vanderhyden BC; Nair P; Weissman BE; Huntsman DG; Trent JM
Clin Cancer Res; 2018 Apr; 24(8):1932-1943. PubMed ID: 29440177
[No Abstract] [Full Text] [Related]
15. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
Scorsone K; Zhang L; Woodfield SE; Hicks J; Zage PE
Invest New Drugs; 2014 Oct; 32(5):815-24. PubMed ID: 24832869
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Yang Q; Tian Y; Liu S; Zeine R; Chlenski A; Salwen HR; Henkin J; Cohn SL
Cancer Res; 2007 Feb; 67(4):1716-24. PubMed ID: 17308113
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.
Chlenski A; Guerrero LJ; Peddinti R; Spitz JA; Leonhardt PT; Yang Q; Tian Y; Salwen HR; Cohn SL
Mol Cancer; 2010 Jun; 9():138. PubMed ID: 20525313
[TBL] [Abstract][Full Text] [Related]
18. Repurposing Ponatinib as a Potent Agent against
Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
[No Abstract] [Full Text] [Related]
19. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis.
Bäckman U; Svensson A; Christofferson RH; Azarbayjani F
Anticancer Res; 2008; 28(3A):1551-7. PubMed ID: 18630510
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
